Sanofi will acquire the London-based vaccine startup Vicebio for $1.15 billion upfront and as much as $450 million in future payments, the companies said Tuesday. The deal marks Sanofi’s fourth acquisition of the year, following the recently completed $9 billion purchase of commercial-stage drugmaker Blueprint Medicines, an Alzheimer’s pipeline expansion with a $470 million deal…
Read article
In 2020, Jaci Hermstad died at age 26 from a rare and aggressive form of ALS. But her story didn’t end there. A drug that was created just for her, called Jacifusen, has since been given to others with mutations in the FUS gene, what’s known as FUS-ALS. The results in the first 12 patients, published…
Read article
At long last, Anne Wojcicki has officially bought 23andMe. The co-founder and former CEO’s nonprofit, TTAM Research Institute, on Monday said it had completed the acquisition of 23andMe’s consumer genetics business and its research unit. In June, Wojcicki’s TTAM won a bid to acquire 23andMe for $305 million as part of bankruptcy proceedings. Regeneron had…
Read article
For biotech companies advancing oncology therapies, regulatory speed can be critical to achieving key milestones and getting new therapies to patients faster. In a recent interview, Josh Taylor, PhD, senior director of regulatory affairs at Allucent, discussed how biotech companies can leverage the FDA’s expedited programs—Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review—to shorten…
Read article
Expected readouts in obesity, lung cancer and atopic dermatitis headline a series of study results that could give the biotechnology sector a boost in another down year.
Read article
Sino Biopharmaceuticals plans to pay up to $950.9 million to acquire LaNova Medicines, which previously licensed drugs to Merck and AstraZeneca.
Read article
The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.
Read article